Expert teams improving interpretation of BRCA1/2 and hereditary breast, ovarian, and pancreatic cancer genes
Curation Expert Panels for BRCA1/2 and Hereditary Breast, Ovarian and Pancreatic (HBOP) Cancer Genes
This project helps doctors and laboratories turn unclear genetic test results in BRCA1/2 and related genes into clear guidance for people at risk of hereditary breast, ovarian, or pancreatic cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11096243 on NIH RePORTER |
What this research studies
Expert panels will apply standardized ClinGen rule-based methods to classify genetic changes in BRCA1, BRCA2, ATM, PALB2, and related genes. They will review laboratory and clinical evidence, including patient-derived genetic test results, to create clear, reproducible classification rules. Validated classifications and guidance will be shared publicly to reduce uncertain or conflicting test reports. Over time the panels will expand to additional hereditary breast, ovarian, and pancreatic (HBOP) genes to help more people get actionable results.
Who could benefit from this research
Good fit: People who have had genetic testing showing variants in BRCA1, BRCA2, ATM, PALB2, or other hereditary breast, ovarian, and pancreatic cancer genes, or those with a strong family history and prior inconclusive results, are most likely to benefit.
Not a fit: People without germline variants in these cancer genes or with conditions unrelated to hereditary breast, ovarian, or pancreatic cancer are unlikely to benefit directly from this work.
Why it matters
Potential benefit: If successful, patients could receive more certain genetic test results that support clearer risk estimates, tailored screening, preventive decisions, and treatment options.
How similar studies have performed: ClinGen variant curation panels and similar expert-driven classification efforts have already improved interpretation for other genes, and this project builds on that established approach.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Couch, Fergus Joseph — Mayo Clinic Rochester
- Study coordinator: Couch, Fergus Joseph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.